News | May 12, 2015

Long-Term Economic Data Shows Savings With Atherectomy in ORBIT II Trial

Diamondback 360 coronary orbital atherectomy system demonstrated one-year cost savings of up to $4,913 per patient

ORBIT II, Diamondback 360, CSI, SCAI 2015, atherectomy

May 12, 2015 — Cardiovascular Systems Inc. (CSI) featured two-year data from its ORBIT II study of the company’s Diamondback 360 coronary orbital atherectomy system (OAS) in a late-breaking presentation at the 2015 Society for Cardiovascular Angiography and Interventions (SCAI) conference. Diamondback 360 is a U.S. Food and Drug Administration (FDA)-approved atherectomy technology indicated for the treatment of severely calcified lesions.

CSI completed ORBIT II enrollment of 443 patients at 49 U.S. medical centers in November 2012. The pivotal study evaluated the safety and efficacy of the company’s orbital atherectomy technology in treating patients with de novo severely calcified coronary lesions. ORBIT II was the first investigational device exemption (IDE) study in history to evaluate this problematic subset of patients. In October 2013, CSI received premarket application (PMA) approval from the FDA to market Diamondback 360 as a treatment for severely calcified coronary arteries to facilitate stent delivery.

Jeffrey Chambers, M.D., of Metropolitan Heart and Vascular Institute, Minneapolis, highlighted new data that demonstrated a high freedom from major adverse cardiac events (MACE) rate, including target lesion revascularization (TLR) and target vessel revascularization (TVR), at two years for this difficult-to-treat patient population.

“ORBIT II two-year data further demonstrates the safety and efficacy of using CSI’s Diamondback 360 orbital atherectomy system to treat severely calcified coronary arteries,” said Chambers. “We have witnessed impressive clinical and economic benefits of using this device in a complex patient population that can be challenging to treat with traditional options. We also know now that using the coronary OAS device prior to stent treatment in severely calcified arteries yields durable, long-term results.”

Chambers presented the following two-year data:

Two-Year Freedom From:

MACE                                                80.6%

MI (CK-MB >3x ULN)*                    90.3%

Non Q-wave                                    91.2%

Q-wave                                            99.1%

TVR/TLR                                        91.9%

TVR                                                97.1%

TLR                                                93.8%

Cardiac Death                               95.7%

*Based on reported CK-MB >3X ULN

Long-term patient outcomes are critical to understanding rates of hospital readmission when evaluating cost savings for the treating institutions and overall healthcare system. The Diamondback 360 Coronary OAS has been associated with a shorter length of stay for patients when the device was used to treat severely calcified lesions to facilitate stent placement compared to treating without the Diamondback 360. The lower incidence of readmission and shorter length of stay provide an estimated cost savings of up to $4,913 per patient to the treating institution at one year following the procedure.

The OAS device offers value with an incremental cost effectiveness ratio (ICER) of $11,895 per life year gained, which is well under the $50,000 per quality-adjusted life year (QALY) threshold, to be considered “high value.”

For more information:

Related Content

Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init